PMID: 7536126May 1, 1995Paper

Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. I-125 implant followed by external-beam radiation

Cancer
F A CritzD Holladay

Abstract

Because results of retropubic I-125 implantation for prostate cancer have been poor, external beam radiation was added postimplant. Serum prostate specific antigen (PSA) was used to assess this approach of combined irradiation. Two hundred and thirty-nine patients with clinical Stage T1 or T2 but surgically node-negative prostate cancer were treated. Results were monitored by serial serum PSA evaluation. Positive clinical findings or a rising PSA level defined recurrent disease. With a median follow-up of 45 months (range, 24-120 months), the Kaplan-Meier projected disease free survival rate was 74% at 5 years and 66% at 10 years. Overall at a 60-month minimum follow-up, 77% of patients had a PSA of 0.5 ng/ml or less. This nadir level is highly predictive of a long term disease free survival, significantly better than pretreatment PSA, grade, or clinical Stage T1 or T2. The PSA-monitored disease free survival rate after combination irradiation appears comparable with that after radical prostatectomy and perhaps superior to that after external-beam radiation. This effect was achieved even though lower-than-usual doses of radiation from both sources were administered. The combination of an I-125 implant followed by external-beam ...Continue Reading

References

Mar 1, 1979·International Journal of Radiation Oncology, Biology, Physics·C C LingW U Shipley
Aug 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G L Andriole
Aug 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A RitterT J Kinsella
Sep 1, 1991·International Journal of Radiation Oncology, Biology, Physics·C A LawtonS R Doggett
Dec 1, 1972·The Journal of Urology·W F WhitmoreH Grabstald
May 1, 1980·The Journal of Urology·J F GaetaG P Murphy
Mar 1, 1981·International Journal of Radiation Oncology, Biology, Physics·G U RaoR Howells

❮ Previous
Next ❯

Citations

Nov 14, 1997·Seminars in Surgical Oncology·H H Holm
Jan 9, 2001·CA: a Cancer Journal for Clinicians·H RagdeA A Elgamal
Sep 1, 2005·Lifetime Data Analysis·Ying Guo, Amita K Manatunga
Jun 27, 2002·Current Urology Reports·Nelson N Stone, Richard G Stock
Aug 1, 1996·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·A L ZietmanW U Shipley
Dec 6, 2000·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·D AshUNKNOWN EORTC Radiotherapy Group
Jun 21, 2002·European Urology·N N Stone, R G Stock
Mar 2, 2002·International Journal of Radiation Oncology, Biology, Physics·Lucille N LeeNelson N Stone
Apr 18, 2002·International Journal of Radiation Oncology, Biology, Physics·Daniel H ClarkeMichael J Sheridan
Jul 4, 1998·International Journal of Radiation Oncology, Biology, Physics·M J ZelefskyZ Fuks
May 29, 1999·International Journal of Radiation Oncology, Biology, Physics·F A ViciniA Martinez
Jul 1, 1999·International Journal of Radiation Oncology, Biology, Physics·S NagR Nath
Mar 8, 2000·International Journal of Radiation Oncology, Biology, Physics·J C BlaskoW Cavanagh
Nov 18, 2003·BJU International·T M de Reijke, M Pilar Laguna
Jul 13, 2013·Biometrics·Ying GuoAmita K Manatunga
Feb 16, 2010·The Urologic Clinics of North America·Richard G Stock, Nelson N Stone
Jan 5, 2005·International Journal of Radiation Oncology, Biology, Physics·Jamie A CesarettiBarry S Rosenstein
Nov 10, 2004·Urology·Clarissa Febles, Richard K Valicenti
Jul 28, 2004·International Journal of Radiation Oncology, Biology, Physics·Richard G StockNelson N Stone
Sep 5, 1998·Cancer Treatment Reviews·M Reni, A Bolognesi
Jun 17, 1998·The Journal of Urology·S I ZeitlinP Albert
Aug 5, 1999·Hematology/oncology Clinics of North America·R G Stock, N N Stone
Nov 1, 1996·The Urologic Clinics of North America·J C BlaskoP D Grimm
May 9, 2003·The Urologic Clinics of North America·Nelson N Stone, Richard G Stock
Oct 14, 2006·Current Opinion in Urology·T LochM Stöckle
Sep 18, 1997·Journal of Surgical Oncology·J SylvesterH Ragde
Jan 25, 2002·Cancer Control : Journal of the Moffitt Cancer Center·R A Zlotecki
Sep 27, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Ayeskanta MohantyIn-Kyu Park
May 1, 1997·The Urologic Clinics of North America·P F SchellhammerG L Wright

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.